companydata.dkcompanydata.dk

AKI Therapeutics A/S: Financial statements 2021

CVR: 37509736

Source: annual report 2021, Danish Business Authority

01/01/2021 – 31/12/2021

AKI Therapeutics A/S (CVR 37509736) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -12,089 and a net result of DKK -1,523,621 compared with DKK 148,172 the year before. Equity in the 2021 report amounted to DKK 3,572,626. The solvency ratio was 75.5%.

Revenue
DKK 0
Gross Profit
DKK -12,089
Profit/Loss
DKK -1,523,621
Equity
DKK 3,572,626
Total Assets
DKK 4,731,528

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
20210-12K-1.5M3.6M-
2020--89K148K115K-
2019--127K28K52K-
2018--5K-5K24K-
2017--4K-13K29K-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like AKI Therapeutics A/S

Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.

Try the lead list generator

Events in 2021

AKI Therapeutics A/S: The 2020 annual report is outJun 23, 2021

AKI Therapeutics A/S has published its annual report for 2020. Gross profit came to DKK -89,304, and the net result was DKK 148,172.

Troels Peter Troelsen joins the board of AKI Therapeutics A/SJun 22, 2021

As of June 22, 2021, Troels Peter Troelsen has joined the board of directors of AKI Therapeutics A/S.

Christian Vinding Thomsen joins the board of AKI Therapeutics A/SJun 22, 2021

As of June 22, 2021, Christian Vinding Thomsen has joined the board of directors of AKI Therapeutics A/S.

Lars Otto Uttenthal joins the board of AKI Therapeutics A/SJun 22, 2021

As of June 22, 2021, Lars Otto Uttenthal has joined the board of directors of AKI Therapeutics A/S.

Troels Ring joins the board of AKI Therapeutics A/SJun 22, 2021

As of June 22, 2021, Troels Ring has joined the board of directors of AKI Therapeutics A/S.

About AKI Therapeutics A/S

AKI Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named AKI Therapeutics ApS and Renoguard ApS. The management consists of Sigbjørn Georg Nielsen Kjærgård. The board consists of Charlotte Pahl, Christian Vinding Thomsen and Lars Otto Uttenthal. The company's owners include NIELS ERIK JESPERSEN HOLDING ApS, Beier Holding ApS and FINANSMANAGEMENT ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,593,852,000 compared with DKK -1,960,091 the year before. Equity in the 2025 report amounted to DKK 551,898,000.

Source: annual report 2025, Danish Business Authority